John R. Moore Sells 31,078 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Stock

Edgewise Therapeutics, Inc. (NASDAQ:EWTXGet Rating) General Counsel John R. Moore sold 31,078 shares of the business’s stock in a transaction on Tuesday, June 21st. The shares were sold at an average price of $7.29, for a total value of $226,558.62. Following the sale, the general counsel now owns 3,000 shares in the company, valued at $21,870. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Shares of EWTX traded up $0.77 during midday trading on Tuesday, reaching $7.40. The stock had a trading volume of 477,279 shares, compared to its average volume of 311,419. The company’s 50-day moving average is $7.19 and its 200 day moving average is $11.29. Edgewise Therapeutics, Inc. has a 12-month low of $5.41 and a 12-month high of $27.87. The company has a market capitalization of $366.86 million, a price-to-earnings ratio of -7.18 and a beta of -0.10.

Edgewise Therapeutics (NASDAQ:EWTXGet Rating) last posted its quarterly earnings data on Wednesday, May 11th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.01). As a group, equities analysts forecast that Edgewise Therapeutics, Inc. will post -1.49 earnings per share for the current fiscal year.

Several equities analysts recently commented on EWTX shares. Royal Bank of Canada started coverage on Edgewise Therapeutics in a research report on Wednesday, April 13th. They set an “outperform” rating and a $31.00 target price for the company. SVB Leerink restated an “outperform” rating on shares of Edgewise Therapeutics in a research report on Monday, April 25th. Finally, The Goldman Sachs Group reduced their target price on Edgewise Therapeutics from $8.00 to $5.00 and set a “neutral” rating for the company in a research report on Tuesday, May 24th.

A number of hedge funds have recently modified their holdings of the stock. Citigroup Inc. boosted its holdings in Edgewise Therapeutics by 155.0% during the 3rd quarter. Citigroup Inc. now owns 1,497 shares of the company’s stock valued at $25,000 after acquiring an additional 910 shares during the period. DekaBank Deutsche Girozentrale boosted its holdings in Edgewise Therapeutics by 10.0% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 19,800 shares of the company’s stock valued at $183,000 after acquiring an additional 1,800 shares during the period. Legal & General Group Plc boosted its holdings in Edgewise Therapeutics by 149.4% during the 4th quarter. Legal & General Group Plc now owns 4,651 shares of the company’s stock valued at $71,000 after acquiring an additional 2,786 shares during the period. Quantum Private Wealth LLC boosted its holdings in Edgewise Therapeutics by 14.9% during the 1st quarter. Quantum Private Wealth LLC now owns 22,242 shares of the company’s stock valued at $215,000 after acquiring an additional 2,890 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Edgewise Therapeutics by 3.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 145,305 shares of the company’s stock valued at $1,410,000 after acquiring an additional 4,910 shares during the period.

About Edgewise Therapeutics (Get Rating)

Edgewise Therapeutics, Inc, a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial.

Featured Stories

Insider Buying and Selling by Quarter for Edgewise Therapeutics (NASDAQ:EWTX)

Receive News & Ratings for Edgewise Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edgewise Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.